My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
January 2014
Patient Care and Science
FDA Approves Simeprevir and Sofosbuvir for Chronic Hepatitis C
In recent weeks the U.S. Food and Drug Administration (FDA) has approved sofosbuvir (Sovaldi) and simeprevir (Olysio) to treat chronic hepatitis C virus (HCV) infection. Sofosbuvir is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.  
 
IDSA offers two email services to help members stay informed of new drug approvals and similar updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
 
Avian Influenza A (H5N1) Virus (1/15/2014, Canadian cases)
 
 
 
IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network (HAN) messages and/or alerts from FDA, and provide your email address and name where indicated.)
 
For more information about the new hepatitis drugs and evolving clinical recommendations from IDSA and liver disease experts, see www.HCVGuidelines.org.

Is Your Facility Experiencing Antibiotic Shortages?

IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at schang@idsociety.org.


Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
FDA Approves Simeprevir and Sofosbuvir for Chronic Hepatitis C
Policy and Advocacy
Congress Approves Partial Relief from Sequestration Funding Cuts
IDSA Supports Diagnostics Bill Moving through House of Representatives
IDSA and PIDS Submit Comments to FDA on Proposed Drug Shortage Rule
Congressional Briefing Highlights Barriers to Immunization for Older Adults
IDSA, SHEA, PIDS Call for Mandatory Immunization of Health Care Personnel
HIVMA Welcomes HIV Policy Assessment Directive in Defense Bill
President Obama Mentions Vaccines and Drug Resistance in State of the Union
Clinical Practice Management
New Resource Helps ID Specialists Prove Their Value
President Obama Signs Bill to Prevent Scheduled Medicare Cut
Science Speaks Blog
The Center for Global Health Policy Examines the Impact of Drug Prices on Vulnerable Populations, and Other Newsworthy Events
You and Your Colleagues
Renew Dues and Update Your Membership
Members on the Move
New Members
In Memoriam: Martin C. McHenry, MD, MS, FIDSA (1932-2013)
Education and Resources
Free Online Course on Antimicrobial Stewardship
Changes to ABIM MOC Now In Effect
Open Forum Infectious Diseases Now Accepting Submissions
Apply Now for the ID Research Careers Meeting
Top Story
From the President: New Website Provides Clinicians with Timely Advice on HCV
ADAPT Act Would Promote New Drug Development
Updated Guideline for Vaccination of Immunocompromised Host Now Available
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.